Alfa Oncology is a leading service provider in PC research and related drug development. We bring together advanced and improved technologies to make scalable peptide screening a reality. Our goal is to help researchers and professionals develop new peptides that specifically targets PC cells for further diagnostic imaging and therapy.
The service offering at Alfa Oncology
Peptides are becoming important directions for new anti-tumor drugs, diagnostic probes and targeted delivery research due to their mild adverse effects, small molecular mass, and strong targeting properties. In order to provide more novel and efficient PC tumor targeting peptides, we provide the following anti-cancer peptide screening strategies and methods, including traditional chromatographic separation, phage display, bio-phenotyping, and so on.
- Activity-directed biochemical and chromatographic separation methods
We offer extraction, isolation, and identification services of natural antitumor peptides. Since peptides are essentially low molecular proteins. We usually prepare peptide fractions by enzymatic digestion, and purify them by gel filtration and reverse chromatography, and use an identification and analysis strategy that combines RNA sequencing and high-resolution liquid chromatography-mass spectrometry (linear ion trap quadrupole-mass spectrometry, LTQ-MS), QE-orbitrap (quadrupole exactive orbitrap) and MALDI-TOF (matrix assisted laser desorption/ionization-time of flight mass spectrometry).
- Artificially designed phage display peptide library screening
Phage display technology is the use of genetic engineering techniques to insert exogenous gene fragments into specific locations of genes and maintain the relative spatial structure and biological activity of recombinant fusion proteins by expressing exogenous gene-encoded proteins or polypeptides on the surface of phages. We use this powerful method to generate and screen peptides that target PC tumor structures.
- PC tumor microenvironment-based peptide screening
The tumor microenvironment includes the tumor, its surrounding mesenchymal cells and the extracellular matrix. The relationship between tumor cells and the microenvironment is like "seed" and "soil", and the development of tumor microenvironment-related drugs is the key to controlling tumor metastasis and invasion. For PC therapeutic development, we are able to offer PC tumor vascular-based peptide screening, tumor metastasis-based peptide screening, and tumor immune-based peptide screening.
- Biophenotype-based peptide screening
We provide model organisms (such as PC genetically engineered mouse models and cancer cell line-derived xenografts, CDXs) and cellular high-content imaging for anti-tumor peptide screening. High content imaging is the simultaneous detection of the effects of the screened sample on cell morphology, growth, differentiation, migration, apoptosis, metabolic pathways and signal transduction, while maintaining the structural and functional integrity of the cells.
If you are interested in our services, please contact us for more details. Our customer service representatives are available 24 hours a day from Monday to Sunday. You can get in touch with our staff directly and receive professional, reliable, and fast feedback.
- Zheng, Lei, et al. "A New Fusion Peptide Targeting Pancreatic Cancer and Inhibiting Tumor Growth." OncoTargets and therapy 13 (2020): 7865.
- Marqus, Susan, Elena Pirogova, and Terrence J. Piva. "Evaluation of the use of therapeutic peptides for cancer treatment." Journal of biomedical science 24.1 (2017): 1-15.